Ann: Board and Management Changes, page-59

First 59 Last

Share
Profile

Follow
RoyE

1,857 Posts.

1003

18/12/23

18:40

Post #: 71512821
Share

Originally posted by Sojourner: ↑

Taking stock for doing nothing? Dorado was only discovered because of Adrian. It was under AC that CVN sold those Thai assets and AC that took the decision to sell those Thai assets to pursue an exploration strategy in the bedout basin.

It was AC that convinced Apache to farm in and drill the first well at Phoenix South-1. At every step of the way, it has been AC that has been driving the exploration plans, and if you didn't notice, his most recent efforts have been focused on securing the funding required for CVN's share of development costs.

Yes there have unfortunately been a series of external events that have occurred which set back timelines but this is through one's fault at CVN. First was the acquisition/merger of Apache by Quadrant, then it was the takeover of Quadrant by Santos, and in between somewhere the whole sector lost about two years due to the covid pandemic. Now there is obviously the potential transaction between Santos and Woodside. None of this is AC's fault and if we are realistic about it, there is nothing anything any junior partner in a similar situation can do about it.

The suggestion that AC has done 'nothing' is just ludicrous when it has been clear AC's most recent efforts has been to put CVN in a position ready to fund its share of costs. You don't have to look too hard across the sector to see how incredibly difficult it is for a junior explorer to get as close AC has put CVN at the moment. Just go and as those guys at Far Limited for example.

Expand

Well said Sojourner and your post is a good summary of AC's considerable achievements at CVN.

CVN Price at posting: 19.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 55 more messages in this thread...

First 59 Last

Add CVN (ASX) to my watchlist

(20min delay)
Last 17.5¢		Change 0.010(6.06%)		Mkt cap ! $313.0M

Open	High	Low	Value	Volume
16.5¢	17.5¢	16.5¢	$208.3K	1.228M

Buyers (Bids)

No.	Vol.	Price($)
2	265525	17.0¢

Sellers (Offers)

Price($)	Vol.	No.
17.5¢	615505	12

View Market Depth

No.	Vol.	Price($)
2	265525	0.170
4	1055635	0.165
4	258985	0.160
7	206587	0.155
7	283335	0.150

Price($)	Vol.	No.
0.175	615505	12
0.180	806225	11
0.185	888213	7
0.190	810388	4
0.195	166549	3

Last trade - 16.10pm 07/10/2024 (20 minute delay)

CVN (ASX) Chart

Ann: Board and Management Changes, page-59

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Board and Management Changes, page-59

Top Stories

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News